Barclays’s Mangoceuticals MGRX Stock Holding History

Barclays’s Portfolio MGRX Stock Details MGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2	Buy	+5	New	+$2	﹤0.01%	5319

Other funds holding MGRX

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ACA

Ackerman Capital Advisors Dallas, Texas $497M AUM 16.31% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Barclays's MGRX Position: Q2 2026 in Review

Barclays opened a new position in Mangoceuticals (MGRX) in Q2 2026: 5 shares worth $2. The stake represents ﹤0.01% of the portfolio and ranks #5319 among its holdings.

18 funds tracked by Wall St. Rank hold MGRX as of Q2 2026.

Barclays held 5 shares of Mangoceuticals worth $2 as of Q2 2026.
Mangoceuticals was a new Barclays position in Q2 2026.
Mangoceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5319 holding.
18 funds tracked by Wall St. Rank held Mangoceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.